Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 4/2016

01-08-2016 | ASNC Information Statement

The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy

Authors: Raymond R. Russell, MD, PhD, FASNC, Jonathan Alexander, MD, Diwakar Jain, MD, Indu G. Poornima, MD, Ajay V. Srivastava, MD, Eugene Storozynsky, MD, PhD, Ronald G. Schwartz, MD, MS

Published in: Journal of Nuclear Cardiology | Issue 4/2016

Login to get access

Abstract

With the increasing number of individuals living with a current or prior diagnosis of cancer, it is important for the cardiovascular specialist to recognize the various complications of cancer and its therapy on the cardiovascular system. This is true not only for established cancer therapies, such as anthracyclines, that have well established cardiovascular toxicities, but also for the new targeted therapies that can have “off target” effects in the heart and vessels. The purpose of this informational statement is to provide cardiologists, cardiac imaging specialists, cardio-oncologists, and oncologists an understanding of how multimodality imaging may be used in the diagnosis and management of the cardiovascular complications of cancer therapy. In addition, this document is meant to provide useful general information concerning the cardiovascular complications of cancer and cancer therapy as well as established recommendations for the monitoring of specific cardiotoxic therapies.
Appendix
Available only for authorised users
Literature
1.
DeSantis CE, Lin CC, Mariotto AB, et al Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.PubMedCrossRef
2.
Felker GM, Thompson RE, Hare JM, et al Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.PubMedCrossRef
3.
Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-50.PubMedCrossRef
4.
Chavez-MacGregor M, Niu J, Zhang N, et al Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer. J Clin Oncol 2015;33:2176-83.PubMedCrossRef
5.
Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25.PubMedPubMedCentralCrossRef
6.
Reulen RC, Winter DL, Frobisher C, et al Long-term cause-specific mortality among survivors of childhood cancer. JAMA 2010;304:172-9.PubMedCrossRef
7.
Colzani E, Liljegren A, Johansson AL, et al Prognosis of patients with breast cancer: Causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 2011;29:4014-21.PubMedCrossRef
8.
Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res 2011;13:R64.PubMedPubMedCentralCrossRef
9.
Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952-60.PubMedCrossRef
10.
Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20-37.PubMedCrossRef
11.
Lipshultz SE, Adams MJ, Colan SD, et al Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions: A scientific statement from the American Heart Association. Circulation 2013;128:1927-95.PubMedCrossRef
12.
Carver JR, Shapiro CL, Ng A, et al American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991-4008.PubMedCrossRef
13.
Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol 2013;20:443-64.PubMedCrossRef
14.
Alexander J, Dainiak N, Berger HJ, et al Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-83.PubMedCrossRef
15.
Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-72.PubMed
16.
Choi BW, Berger HJ, Schwartz PE, et al Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 1983;106:638-43.PubMedCrossRef
17.
Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15.PubMedCrossRef
18.
Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-36.PubMedCrossRef
19.
Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003;10:132-9.PubMedCrossRef
20.
Schwartz RG, McKenzie WB, Alexander J, et al Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109-18.PubMedCrossRef
21.
Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.PubMedCrossRef
22.
Yeh ETH, Tong AT, Lenihan DJ, et al Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 2004;109:3122-31.PubMedCrossRef
23.
Zhang S, Liu X, Bawa-Khalfe T, et al Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-42.PubMedCrossRef
24.
25.
Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med 1978;65:823-32.PubMedCrossRef
26.
Dazzi H, Kaufmann K, Follath F. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich, Switzerland, between 1990 and 1996. Ann Oncol 2001;12:963-6.PubMedCrossRef
27.
Cardinale D, Colombo A, Bacchiani G, et al Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-8.PubMedCrossRef
28.
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003;97:2869-79.PubMedCrossRef
29.
Von Hoff DD, Layard MW, Basa P, et al Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.CrossRef
30.
Panjrath GS, Patel V, Valdiviezo CI, Narula N, Narula J, Jain D. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol 2007;49:2457-64.PubMedCrossRef
31.
Wojnowski L, Kulle B, Schirmer M, et al NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62.PubMedCrossRef
32.
Mackey JR, Clemons M, Cote MA, et al Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008;15:24-35.PubMedPubMedCentralCrossRef
33.
Ewer MS, Vooletich MT, Durand JB, et al Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6.PubMedCrossRef
34.
Hedhli N, Dobrucki LW, Kalinowski A, et al Endothelial-derived neuregulin is an important mediator of ischaemia-induced angiogenesis and arteriogenesis. Cardiovasc Res 2012;93:516-24.PubMedCrossRef
35.
36.
37.
Curigliano G, Cardinale D, Suter T, et al Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23 Suppl 7:vii155-66.
38.
Hooning MJ, Botma A, Aleman BM, et al Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99:365-75.PubMedCrossRef
39.
McGale P, Darby SC, Hall P, et al Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011;100:167-75.PubMedCrossRef
40.
Marks LB, Yu X, Prosnitz RG, et al The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005;63:214-23.PubMedCrossRef
41.
Seddon B, Cook A, Gothard L, Salmon E, Latus K, Underwood SR, et al Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol 2002;64:53-63.PubMedCrossRef
42.
Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 2007;25:3031-7.PubMedCrossRef
43.
Gayed IW, Liu HH, Wei X, et al Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol 2009;4:179-84.PubMedCrossRef
44.
Gabriels K, Hoving S, Seemann I, et al Local heart irradiation of ApoE(−/−) mice induces microvascular and endocardial damage and accelerates coronary atherosclerosis. Radiother Oncol 2012;105:358-64.PubMedCrossRef
45.
Seemann I, Gabriels K, Visser NL, et al Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature. Radiother Oncol 2012;103:143-50.PubMedCrossRef
46.
Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005;97:419-24.PubMedPubMedCentralCrossRef
47.
Patt DA, Goodwin JS, Kuo YF, et al Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005;23:7475-82.PubMedCrossRef
48.
Yu X, Prosnitz RR, Zhou S, et al Symptomatic cardiac events following radiation therapy for left-sided breast cancer: Possible association with radiation therapy-induced changes in regional perfusion. Clin Breast Cancer 2003;4:193-7.PubMed
49.
Lancellotti P, Nkomo VT, Badano LP, et al Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2013;26:1013-32.PubMedCrossRef
50.
Van Kriekinge SD, Berman DS, Germano G. Automatic quantification of left ventricular ejection fraction from gated blood pool SPECT. J Nucl Cardiol 1999;6:498-506.PubMedCrossRef
51.
Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: A critical review. Ann Oncol 1990;1:409-14.PubMed
52.
de Forni M, Malet-Martino MC, Jaillais P, et al Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study. J Clin Oncol 1992;10:1795-801.PubMed
53.
Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: Revisited. Expert Opin Drug Saf 2009;8:191-202.PubMedCrossRef
54.
Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994;28:374-8.PubMed
55.
Berliner S, Rahima M, Sidi Y, Teplitsky Y, et al Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990;8:583-6.PubMedCrossRef
56.
Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002;13:797-801.PubMedCrossRef
57.
Schmidinger M, Zielinski CC, Vogl UM, et al Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-12.
58.
59.
Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc 2014;3:e000665.PubMedPubMedCentralCrossRef
60.
Chintalgattu V, Rees ML, Culver JC, et al Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med 2013;5:187ra69.
61.
Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 2011;10:111-26.PubMedCrossRef
62.
Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704-12.PubMed
63.
Saito K, Takeda K, Imanaka-Yoshida K, Imai H, Sekine T, Kamikura Y. Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: Comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med 2003;17:481-8.PubMedCrossRef
64.
Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 2002;16:11-20.PubMed
65.
Dutcher J, Atkins MB, Margolin K, et al Kidney cancer: The Cytokine Working Group experience (1986-2001): Part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001;18:209-19.PubMedCrossRef
66.
Atkins MB, Lotze MT, Dutcher JP, et al High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.PubMed
67.
Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21:371-81.PubMedPubMedCentralCrossRef
68.
Yu C, Chopra IJ, Ha E. A novel melanoma therapy stirs up a storm: Ipilimumab-induced thyrotoxicosis. Endocrinol Diabetes Metab Case Rep 2015;2015:140092.PubMedPubMedCentral
69.
Wackers FJ, Berger HJ, Johnstone DE, et al Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: Validation of the technique and assessment of variability. Am J Cardiol 1979;43:1159-66.PubMedCrossRef
70.
Corbett JR, Akinboboye OO, Bacharach SL, et al Equilibrium radionuclide angiocardiography. J Nucl Cardiol 2006;13:e56-79.PubMedCrossRef
71.
Marshall RC, Berger HJ, Reduto LA, Gottschalk A, Zaret BL. Variability in sequential measures of left ventricular performance assessed with radionuclide angiocardiography. Am J Cardiol 1978;41:531-6.PubMedCrossRef
72.
Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61:77-84.PubMedCrossRef
73.
Walker J, Bhullar N, Fallah-Rad N, et al Role of three-dimensional echocardiography in breast cancer: Comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010;28:3429-36.PubMedCrossRef
74.
de Geus-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, et al Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med 2011;52:560-71.PubMed
75.
Tassan-Mangina S, Codorean D, Metivier M, et al Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006;7:141-6.PubMedCrossRef
76.
Palmeri ST, Bonow RO, Myers CE, et al Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986;58:607-13.PubMedCrossRef
77.
Groch MW, DePuey EG, Belzberg AC, et al Planar imaging versus gated blood-pool SPECT for the assessment of ventricular performance: A multicenter study. J Nucl Med 2001;42:1773-9.PubMed
78.
Adachi I, Akagi H, Umeda T, et al Gated blood pool SPECT improves reproducibility of right and left ventricular Fourier phase analysis in radionuclide angiography. Ann Nucl Med 2003;17:711-6.PubMedCrossRef
79.
Lefrak E, Pitha J, Rosenheim S, et al A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.PubMedCrossRef
80.
Clements IP, Brinkmann B, Mullan BP, O’Connor MK, Breen JF. MCGregor CG. Operator-interactive method for simultaneous measurement of left and right ventricular volumes and ejection fraction by tomographic electrocardiography-gated blood pool radionuclide ventriculography. J Nucl Cardiol 2006;13:50-63.PubMedCrossRef
81.
Daou D, Harel F, Helal BO, et al Electrocardiographically gated blood-pool SPECT and left ventricular function: Comparative value of 3 methods for ejection fraction and volume estimation. J Nucl Med 2001;42:1043-9.PubMed
82.
Jensen MM, Schmidt U, Huang C, Zerahn B. Gated tomographic radionuclide angiography using cadmium-zinc-telluride detector gamma camera; comparison to traditional gamma cameras. J Nucl Cardiol 2014;21:384-96.PubMedCrossRef
83.
84.
Cottin Y, Touzery C, Dalloz F, et al Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: Evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 1998;21:665-70.PubMedCrossRef
85.
Schwartz RG, Venci N. Can serial changes of diastolic dysfunction signal incremental risk of chemotherapy-induced heart failure missed by the timing of declining LV ejection fraction? J Nucl Cardiol 2015. doi:10.​1007/​s12350-015-0194-4.
86.
Gerber TC, Gibbons RJ. Weighing the risks and benefits of cardiac imaging with ionizing radiation. JACC Cardiovasc Imaging 2010;3:528-35.PubMedCrossRef
87.
Fiechter M, Stehli J, Fuchs TA, Dougoud S, Gaemperli O, Kaufmann PA. Impact of cardiac magnetic resonance imaging on human lymphocyte DNA integrity. Eur Heart J 2013;34:2340-5.PubMedPubMedCentralCrossRef
88.
89.
Mor-Avi V, Lang RM. Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy? J Am Coll Cardiol 2013;61:85-7.PubMedCrossRef
90.
Mulvagh SL, Rakowski H, Vannan MA, et al American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am Soc Echocardiogr 2008;21:1179-201; quiz 281.
91.
Banchs J, Jefferies JL, Plana JC, Hundley WG. Imaging for cardiotoxicity in cancer patients. Tex Heart Inst J 2011;38:268-9.PubMedPubMedCentral
92.
Marchandise B, Schroeder E, Bosly A, et al Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92-8.PubMedCrossRef
93.
Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992;20:62-9.PubMedCrossRef
94.
Civelli M, Cardinale D, Martinoni A, et al Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. Int J Cardiol 2006;111:120-6.PubMedCrossRef
95.
Plana JC, Galderisi M, Barac A, et al Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911-39.PubMedCrossRef
96.
Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review. J Am Coll Cardiol 2014;63:2751-68.PubMedCrossRef
97.
98.
Sawaya H, Sebag IA, Plana JC, et al Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596-603.PubMedPubMedCentralCrossRef
99.
Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010;53:121-9.PubMedCrossRef
100.
Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: Systematic review of the literature and recommendations for use. Am J Clin Pathol 2008;130:688-95.PubMedCrossRef
101.
Fallah-Rad N, Walker JR, Wassef A, et al The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.PubMedCrossRef
102.
Jurcut R, Wildiers H, Ganame J, et al Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 2008;21:1283-9.PubMedCrossRef
103.
Hendel RC, Patel MR, Kramer CM, et al ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: A report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol 2006;48:1475-97.PubMedCrossRef
104.
Zagrosek A, Abdel-Aty H, Boye P, Wassmuth R, Messroghli D, Utz W, et al Cardiac magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. JACC Cardiovasc Imaging 2009;2:131-8.PubMedCrossRef
105.
Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008;10:5.PubMedPubMedCentralCrossRef
106.
Lightfoot JC, D’Agostino RB Jr, Hamilton CA, et al Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging 2010;3:550-8.PubMedPubMedCentralCrossRef
107.
Corapcioglu F, Sarper N, Berk F, Sahin T, Zengin E, Demir H. Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: A comparative study with echocardiography and multigated radionuclide angiography. Pediatr Hematol Oncol 2006;23:71-80.PubMedCrossRef
108.
Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699-709.PubMedCrossRef
109.
Cardinale D, Colombo A, Lamantia G, et al Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-20.PubMedCrossRef
110.
Voigt J, John MS, Taylor A, Krucoff M, Reynolds MR, Gibson CM. A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. Clin Cardiol 2014;37:312-21
111.
Lestuzzi C, Vaccher E, Talamini R, et al Effort myocardial ischemia during chemotherapy with 5-fluorouracil: An underestimated risk. Ann Oncol 2014;25:1059-64.PubMedCrossRef
112.
El Fadl MHA, Bagai RK, Spiro TP, Daw HA. 5-Fluorouracil-induced cardiotoxicity during chemotherapy for adenocarcinoma of the small bowel. Gastrointest Cancer Res 2009;3:167-70
113.
Heidenreich PA, Kapoor JR. Radiation induced heart disease: Systemic disorders in heart disease. Heart 2009;95:252-8.PubMedCrossRef
114.
Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 2008;121:e387-96.PubMedCrossRef
115.
Campbell BA, Voss N, Pickles T, et al Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: A question of field size. J Clin Oncol 2008;26:5170-4.PubMedCrossRef
116.
Hughes S, Liong J, Miah A, et al A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 2008;3:648-51.PubMedCrossRef
117.
Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging 2010;3:623-40.PubMedCrossRef
118.
119.
Burke A, Virmani R. Tumors of the heart and the great vessels. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology 1996.
120.
von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: Current applications and future directions. Radiology 2006;238:405-22.CrossRef
121.
Meng Q, Lai H, Lima J, Tong W, Qian Y, Lai S. Echocardiographic and pathologic characteristics of primary cardiac tumors: A study of 149 cases. Int J Cardiol 2002;84:69-75.PubMedCrossRef
122.
Best AK, Dobson RL, Ahmad AR. Best cases from the AFIP: Cardiac angiosarcoma. Radiographics 2003;23 Spec No:S141-5.
123.
Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T. Cardiac tumours: Diagnosis and management. Lancet Oncol 2005;6:219-28.PubMedCrossRef
124.
125.
126.
127.
Aktolun C, Bayhan H, Kir M. Clinical experience with Tc-99 m MIBI imaging in patients with malignant tumors. Preliminary results and comparison with Tl-201. Clin Nucl Med 1992;17:171-6.PubMedCrossRef
128.
Coleman RE. Single photon emission computed tomography and positron emission tomography in cancer imaging. Cancer 1991;67:1261-70.PubMedCrossRef
129.
Yigitbasi OG, Tutus A, Bozdemir K, Nardali M, Guney E. 201Tl imaging for differentiating between malignant and benign neck masses. Nucl Med Commun 1998;19:555-60.PubMedCrossRef
130.
Ruggiero NJ 2nd, Doherty JU, Ferrari VA, Hansen CL. Myocardial perfusion defect caused by intramyocardial lipoma. J Nucl Cardiol 2008;15:286-9.PubMedCrossRef
131.
Mansi L, Rambaldi PF, Cuccurullo V, et al Diagnostic and prognostic role of 99 mTc-Tetrofosmin in breast cancer. Q J Nucl Med 1997;41:239-50.PubMed
132.
Williams KA, Hill KA, Sheridan CM. Noncardiac findings on dual-isotope myocardial perfusion SPECT. J Nucl Cardiol 2003;10:395-402.PubMedCrossRef
133.
Fletcher JW, Djulbegovic B, Soares HP, et al Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508.PubMedCrossRef
134.
Fischman AJ. Positron emission tomography in the clinical evaluation of metastatic cancer. J Clin Oncol 1996;14:691-6.PubMed
135.
Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 1999;175:356-73.PubMedCrossRef
136.
Dhull VS, Sharma P, Mukherjee A, Jana M, Bal C, Kumar R. 18F-FDG PET-CT for evaluation of cardiac angiosarcoma: A case report and review of literature. Mol Imaging Radionucl Ther 2015;24:32-6.PubMedPubMedCentralCrossRef
137.
Freudenberg LS, Rosenbaum SJ, Schulte-Herbruggen J, et al Diagnosis of a cardiac angiosarcoma by fluorine-18 fluorodeoxyglucose positron emission tomography. Eur Radiol 2002;12:S158-61.PubMed
138.
Higashiyama S, Kawabe J, Hayashi T, et al Effectiveness of preoperative PET examination of huge angiosarcoma of the heart. Clin Nucl Med 2009;34:99-102.PubMedCrossRef
139.
Hori Y, Funabashi N, Miyauchi H, Nakagawa K, Shimura H, Miyazaki M, et al Angiosarcoma in the right atria demonstrated by fusion images of multislice computed tomography and positron emission tomography using F-18 Fluoro-Deoxyglucose. Int J Cardiol 2007;123:e15-7.PubMedCrossRef
140.
141.
Butany J, Leong SW, Carmichael K, Komeda M. A 30-year analysis of cardiac neoplasms at autopsy. Can J Cardiol 2005;21:675-80.PubMed
142.
Nonaka A, Stugaard M, Ueda O, Hara H, Shimada T, Shiotani H. Fluorodeoxyglucose-positron emission tomography differentiating thrombus from tumor in the left ventricle. J Am Coll Cardiol 2009;53:894.PubMedCrossRef
143.
Tong AK, Mann KP, Schuster DM, Yan X. A rare presentation of myocardial plasmacytoma assessed by FDG PET/CT. Clin Nucl Med 2014;39:643-5.PubMedCrossRef
144.
Rahbar K, Seifarth H, Schafers M, et al Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J Nucl Med 2012;53:856-63.PubMedCrossRef
145.
Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001;42:1062-76.PubMed
146.
Olmos RAV, ten Bokkel Huinink WW, ten Hoeve RF, et al Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer 1995;31A:26-31.
147.
Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (mIBG) parameters in patients with heart failure: A systematic review. Eur Heart J 2008;29:1147-59.PubMedCrossRef
148.
Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-mIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36:2044-9.PubMed
149.
Carrio I, Lopez-Pousa A, Estorch M, Duncker D, Berna L, Torres G, et al Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 1993;34:1503-7.PubMed
150.
Bennink RJ, van den Hoff MJ, van Hemert FJ, et al Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med 2004;45:842-8.PubMed
151.
Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330-52.PubMedCrossRef
152.
Gabrielson KL, Mok GS, Nimmagadda S, et al Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99 m annexin V single-photon emission computed tomography. Mol Imaging 2008;7:132-8.PubMedPubMedCentral
153.
Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, et al Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004;37:837-46.PubMedCrossRef
154.
Narula J, Acio ER, Narula N, et al Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001;7:1347-52.PubMedCrossRef
155.
Su H, Gorodny N, Gomez LF, et al Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity. Circ Cardiovasc Imaging 2015;8:e001952.PubMedPubMedCentralCrossRef
156.
Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001;37:4-9.PubMedCrossRef
157.
Cardinale D, Sandri MT, Martinoni A, et al Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13:710-5.PubMedCrossRef
158.
Cardinale D, Sandri MT, Martinoni A, et al Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-22.PubMedCrossRef
159.
Carrio I, Estorch M, Berna L, Germá JR, Alonso C, Ojeda B, et al Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med 1991;18:806-12.PubMedCrossRef
160.
Hiroe M, Ohta Y, Fujita N, Nagata M, Toyozaki T, Kusakabe K, et al Myocardial uptake of 111In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats. Morphological and hemodynamic findings. Circulation 1992;86:1965-72.PubMedCrossRef
161.
Estorch M, Carrio I, Berna L, Martínez-Duncker C, Alonso C, Germá JR, et al Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 1990;31:1965-9.PubMed
162.
Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.PubMedCrossRef
163.
Olmos RAV, ten Bokkel Huinink WW, Greve JC, Hoefnagel CA. I-123 mIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med 1992;17:163-7.
164.
Takano H, Ozawa H, Kobayashi I, Hamaoka S, Nakajima A, Nakamura T, et al Atrophic nerve fibers in regions of reduced mIBG uptake in doxorubicin cardiomyopathy. J Nucl Med 1995;36:2060-1.PubMed
165.
Wakasugi S, Fischman AJ, Babich JW. Metaiodobenzylguanidine: Evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med 1993;34:1283-6.PubMed
166.
Takeishi Y, Sukekawa H, Sakurai T, Saito H, Nishimura S, Shibu T, et al Noninvasive identification of anthracycline cardiotoxicity: Comparison of 123I-mIBG and 123I-BMIPP imaging. Ann Nucl Med 1994;8:177-82.PubMedCrossRef
167.
Nousiainen T, Vanninen E, Jantunen E, Remes J, Kuikka J, Hartikainen J. Anthracycline-induced cardiomyopathy: Long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. Clin Physiol 2001;21:123-8.PubMedCrossRef
168.
169.
Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276-82.PubMedCrossRef
170.
de Korte MA, de Vries EG, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WTA, et al 111 Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007;43:2046-51.PubMedCrossRef
171.
Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.PubMedPubMedCentralCrossRef
172.
Merlini G, Narula J, Arbustini E. Molecular imaging of misfolded protein pathology for early clues to involvement of the heart. Eur J Nucl Med Mol Imaging 2014;41:1649-51.PubMedCrossRef
173.
Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54:213-20.PubMedCrossRef
174.
Dorbala S, Vangala D, Semer J, Strader C, Bruyere Jr JR, Di Carli MF, et al Imaging cardiac amyloidosis: A pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62.PubMedCrossRef
Metadata
Title
The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy
Authors
Raymond R. Russell, MD, PhD, FASNC
Jonathan Alexander, MD
Diwakar Jain, MD
Indu G. Poornima, MD
Ajay V. Srivastava, MD
Eugene Storozynsky, MD, PhD
Ronald G. Schwartz, MD, MS
Publication date
01-08-2016
Publisher
Springer US
Published in
Journal of Nuclear Cardiology / Issue 4/2016
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-016-0538-8

Other articles of this Issue 4/2016

Journal of Nuclear Cardiology 4/2016 Go to the issue

Debate Article

Newer generation cameras are preferred

Original Article

The characterization and prognostic significance of right ventricular glucose metabolism in non-ischemic dilated cardiomyopathy

Original Article

Accurate analysis and visualization of cardiac 11C-PIB uptake in amyloidosis with semiautomatic software

Editorial

Positron emission tomography: An additional prognostic tool in dilated cardiomyopathy?

Editor's Page

So We May Not Forget!

Debate Article

Traditional gamma cameras are preferred

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits